Navigation Links
Lung Cancer Research Bill Introduced in the U.S. House of Representatives: Companion to Senate Mortality Reduction Bill
Date:4/27/2009

WASHINGTON, April 27 /PRNewswire-USNewswire/ -- Lung Cancer Alliance announced that a comprehensive lung cancer research funding bill targeting lung cancer's high mortality rate was introduced with bipartisan support today in the U.S. House of Representatives today.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

"We now have legislation authorizing a broad new comprehensive, multi-agency approach to lung cancer in both Houses of Congress. This is a milestone -- the turning point we are all looking for in federal policy on lung cancer," said LCA President and CEO Laurie Fenton Ambrose.

"We are deeply grateful to the bill's primary sponsors, Congresswoman Donna M. Christensen (D-VI) and Congressman Frank A. LoBiondo (R-NJ), for their continuing leadership on this issue," she said.

Congresswomen Christensen, now in her seventh term, is the first female doctor ever elected to the House of Representatives, a member of the powerful Energy and Commerce Committee which has jurisdiction over health policy and chair of the Congressional Black Caucus Health Braintrust.

"The toll of lung cancer is enormous. It is the biggest cancer killer in every ethnic group, taking more lives each year than the next four most common cancers combined," Congresswoman Christensen said. "With over 60% of new cases being diagnosed in people who never smoked or who had already quit, we need to address this disease as a priority with a more comprehensive strategy."

Congressman LoBiondo, in his eighth term, has been a key legislator on transportation, national security and environmental issues.

"There has been some progress in developing treatments and reducing mortality in lung cancer, but much more can and needs to be done," said Congressman LoBiondo. "My family knows firsthand of the toll lung cancer takes, and I believe this added investment into research and treatment is a necessity."

Similar legislation was introduced in the Senate earlier this year by Senator Dianne Feinstein (D-CA) and Senator Sam Brownback (R-KS), who co-chair the Senate Cancer Coalition.

In the 110th Congress, both the House and the Senate passed resolutions urging the administration to make lung cancer research a priority.

The new House and Senate bills, both entitled the Lung Cancer Mortality Reduction Act of 2009, authorize in law a broad comprehensive program that requires all the research related agencies within the Departments of Health and Human Services, Defense and Veterans Administration to coordinate on a strategy for reducing lung cancer's high mortality rate. Annual progress reports to Congress are also required.

The bill calls for $75 million in the first year to launch the program with such sums as may be necessary in the ensuing four years to accomplish the mortality reduction goal.

"When the war on cancer was launched nearly 40 years ago, lung cancer's 5-year survival rate was 13%. Today it is still only 15% and that is unacceptable. What our leaders in Congress are saying with this legislation is, 'We can and must do better,'" said Fenton Ambrose.

Lung Cancer Alliance (www.lungcanceralliance.org) is the only national non-profit organization solely dedicated to patient support and advocacy for the lung cancer community. LCA's mission is to lead the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

    Media Contact:
    Kay Cofrancesco
    kay@lungcanceralliance.org
    202-744-1541



'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Drug May Help Against Inflammatory Breast Cancer
2. Heart, Bone Problems May Follow Prostate Cancer Treatment
3. Further Testing With Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Cancer in Breast Cancer Patients, Changes Surgical Management
4. MesotheliomaHelp.net Announces Expanded Information on Lung Cancer and Mesothelioma Specialists
5. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
6. Scientists discover how to improve immune response to cancer at Princess Margaret Hospital
7. Statins Guard Against Prostate Cancer
8. Statins may exert influence on prostate cancer growth by reducing inflammation
9. Major statin study reveals several important findings for reducing prostate cancer and disease
10. Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence
11. Robotic approach to urothelial cancer of the kidney proves to be beneficial for patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... distinction of Customer Excellence upon National Registry of Emergency Medical Technicians ... drives Financial Performance,” said Dr. Jan G. West, Ph.D. , CEO & ...
(Date:4/26/2017)... ... , ... Miami native and local periodontist Dr. John Paul Gallardo ... back in 1991 that this journey would have taken me into so many learning ... Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... topical cream that’s the first in a new class of photodynamic cosmetics (PDC). ... appearance of skin, visibly reduce outward signs of aging, and minimize the appearance ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology: